This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (15)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

PETER BUINAUSKAS, M.D.; JOHN A. McCREDIE, M.D.; E. R. BROWN, M.D.; WARREN H. COLE, M.D.

AMA Arch Surg. 1959;79(3):432-439.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Recently there has been increasing interest in the immunological treatment of cancer. The ultimate aim of the immunologist is to produce an active immunity against cancer. However, the more limited goal of treatment using the principle of passive immunity is now being extensively investigated. Recent work by other workers has shown that it is possible to produce anticancer antibodies in another species of animal, and these antibodies are active when injected back into the animal from which the tumor was derived. The antibodies have been labeled with radioactive iodine and with fluorescein and have been shown to react with the tumor tissue both in vivo and in vitro. These anticancer antibodies appear to be present mainly in the -globulin fraction of the plasma.

In 1954, Nungester and Fisher 1 prepared an anticancer serum which was effective in decreasing the number of tumor "takes." They gave six injections of a filtrate . . . [Full Text PDF of this Article]

Author Affiliations
Kankakee, Ill.; London, Ont., Canada; Austin, Texas; Chicago

Department of Surgery, University of Illinois.

Footnotes
Received for publication March 30, 1959.

Read at the 16th Annual Meeting of the Central Surgical Association, Montreal, Feb. 21, 1959.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?